Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (P30DK046200, R01DK107859, R01DK105072)
National Heart, Lung, and Blood Institute (K99HL153795, R01HL113338, K01HL143034, R35HL135818)
National Human Genome Research Institute (U01HG008685)
NIH Office of the Director (OT2OD026553)
Received: 30 August 2021
Accepted: 23 November 2021
First Online: 12 January 2022
: All recruited patients provided written consent upon enrollment. At the time of analysis (03/2021), a total of 123,844 patients have consented. The present study protocol was approved by the MGB Institutional Review Board (#2009P002312, #2018P002276).
: Not applicable.
: HSD, NM, BEC, TH, EWK, and RS have no competing interests. SR reports grant and consulting support from Jazz Pharma, and consulting fees from Eisai Pharma, Apnimed Inc and Eli Lilly Inc.